REVOLUTIONARY DERMATOLOGY TECHNOLOGY
At MellingMedical, we have been impressed by the innovative strides made by Damae Medical in the field of dermatology. Founded in 2014 and headquartered in Paris, Damae Medical has introduced a breakthrough in medical imaging with its proprietary technology, LC-OCT (Line-field Confocal Optical Coherence Tomography). As a non-invasive alternative to traditional surgical biopsies, often described as a “digital biopsy,” this technology offers a promising solution for the diagnosis and management of skin cancer.
The American Academy of Dermatology has reported that America’s active duty service members and veterans have an increased risk of developing skin cancer, including melanoma, so Damae’s screening technology can be an important tool in the fight to preserve veteran health
Damae Medical’s LC-OCT technology ingeniously merges the deep imaging capability of Optical Coherence Tomography with the high-resolution imaging of Confocal Microscopy. This combination allows dermatologists to access detailed, 3D images of individual skin cells and structures, such as the dermo-epidermal junction, in real-time. With this advancement, dermatologists can perform precise assessments without the need for cutting the skin, ultimately benefiting patient comfort and outcomes.
The deepLive device, a handheld imaging probe, stands as Damae Medical’s flagship product. It provides instant, “histology-like” images, identifying skin conditions such as Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma at the bedside. Recently, Damae Medical integrated AI-driven diagnostic support into the deepLive device, further amplifying its capability to assist dermatologists, particularly those with less experience, in detecting BCC with sensitivity rates as high as 98%. Beyond diagnosis, the device plays a crucial role in surgical planning by mapping tumor margins, optimizing both treatment effectiveness and preservation of healthy skin.
Recognized for its regulatory compliance, deepLive received the CE Mark Class IIa under the European Medical Device Regulation in 2024, facilitating its utilization across Europe. The growing global presence of Damae Medical’s technology, now implemented in over 40 major referral centers in more than 10 countries, underscores its significant impact on dermatology.
FACILITATING FEDERAL PROCUREMENT
MellingMedical is dedicated to enhancing the accessibility of revolutionary dermatology solutions, such as those provided by Damae Medical, across federal healthcare systems. We ensure that federal healthcare facilities, including those serving veterans and their increased risk of skin cancer, have structured and compliant pathways to procure advanced medical technologies. MellingMedical‘s comprehensive understanding of procurement protocols supports dermatologists in accessing innovative tools like Damae Medical’s deepLive device, enabling improved diagnostic accuracy and patient care within the federal healthcare landscape. By navigating complex regulatory requirements, MellingMedical enables facilities to incorporate cutting-edge technology seamlessly, optimizing patient outcomes while adhering to federal standards.